Aegerion Pharmaceuticals

Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Company's products include Juxtapid (lomitapide) and MYALEPT (metreleptin). Lomitapide is a small molecule microsomal triglyceride transfer protein, which is marketed under the brand name Juxtapid (lomitapide) capsules (Juxtapid) in the United States as an adjunct to a low-fat diet and other lipid-lowering treatments. Lomitapide was also approved in the European Union under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA), as a treatment for homozygous familial hypercholesterolemia (HoFH) in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor and is available as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
Company Growth (employees)
Cambridge, US
Size (employees)
318 (est)
Aegerion Pharmaceuticals was founded in 2005 and is headquartered in Cambridge, US

Aegerion Pharmaceuticals Office Locations

Aegerion Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
101 Main St

Aegerion Pharmaceuticals Metrics

Aegerion Pharmaceuticals Financial Metrics

Net income (2015)

($73.3 m)

Market capitalization (29-Nov-2016)

$58.2 m

Closing share price (29-Nov-2016)


Cash (31-Dec-2015)

$64.5 m
Aegerion Pharmaceuticals's current market capitalization is $58.2 m.
FY, 2013FY, 2014FY, 2015

Operating expense total

$105.9 m$170.7 m$232.7 m


($62.3 m)($26.7 m)($45.2 m)

Net Income

($63.4 m)($39.4 m)($73.3 m)
FY, 2013FY, 2014FY, 2015


$61 m$375.9 m$64.5 m

Accounts Receivable

$7.6 m$17.1 m$13.6 m


$1.6 m$9.5 m$58.7 m

Current Assets

$140.5 m$407.4 m$175.9 m


$1.7 m$4.7 m$4.9 m


$9.6 m

Total Assets

$142.3 m$417.5 m$434.2 m

Accounts Payable

$4.1 m$9.7 m$10.8 m

Current Liabilities

$24.8 m$39.8 m$86.9 m

Additional Paid-in Capital

$369.1 m$491 m$519.2 m

Retained Earnings

($256.1 m)($295.5 m)($368.8 m)

Total Equity

$113 m$160.3 m$115.5 m

Financial Leverage

1.3 x2.6 x3.8 x
FY, 2013FY, 2014FY, 2015

Net Income

($63.4 m)($39.4 m)($73.3 b)

Depreciation and Amortization

$469 k$1.2 m

Accounts Receivable

($7.6 m)($9.6 m)$13.6 m


($1.6 m)($10 m)$58.7 m

Accounts Payable

($1.1 m)$5.5 m$10.8 m

Cash From Operating Activities

($38.4 m)($2.1 m)($311.4 m)

Purchases of PP&E

($716 k)($3.9 m)

Cash From Investing Activities

($22.8 m)$60.2 m

Cash From Financing Activities

$85 m$255.7 m

Interest Paid

$638 k$402 k

Income Taxes Paid

$115 k$1.1 m

Aegerion Pharmaceuticals Market Value History

Aegerion Pharmaceuticals Online Presence

Aegerion Pharmaceuticals Company Life

You may also be interested in